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AbstrACt
Introduction ‘Real world’ bleeding in patients exposed 
to different regimens of dual antiplatelet therapy (DAPT) 
and triple therapy (TT, DAPT plus an anticoagulant) have a 
clinical and economic impact but have not been previously 
quantified.
Methods and analysis We will use linked Clinical 
Practice Research Datalink (CPRD) and Hospital Episode 
Statistics (HES) data to assemble populations eligible 
for three ‘target trials’ in patient groups: percutaneous 
coronary intervention (PCI); coronary artery bypass 
grafting (CABG); conservatively managed (medication only) 
acute coronary syndrome (ACS). Patients ≥18 years old 
will be eligible if, in CPRD records, they have: ≥1 year of 
data before the index event; no prescription for DAPT or 
anticoagulants in the preceding 3 months; a prescription 
for aspirin or DAPT within 2 months after discharge from 
the index event. The primary outcome will be any bleeding 
event (CPRD or HES) up to 12 months after the index event. 
We will estimate adjusted HR for time to first bleeding 
event comparing: aspirin and clopidogrel (reference) 
versus aspirin and prasugrel or aspirin and ticagrelor after 
PCI; and aspirin (reference) versus aspirin and clopidogrel 
after CABG and ACS. We will describe rates of bleeding 
in patients prescribed TT (DAPT plus an anticoagulant). 
Potential confounders will be identified systematically 
using literature review, semistructured interviews with 
clinicians and a short survey of clinicians. We will conduct 
sensitivity analyses addressing the robustness of results 
to the study’s main limitation—that we will not be able to 
identify the intervention group for patients whose bleeding 
event occurs before a DAPT prescription in CPRD.
Ethics and dissemination This protocol was approved 
by the Independent Scientific Advisory Committee for the 
UK Medicines and Healthcare Products Regulatory Agency 
Database Research (protocol 16_126R) and the South 
West Cornwall and Plymouth Research Ethics Committee 
(17/SW/0092). The findings will be presented in peer-
reviewed journals, lay summaries and briefing papers to 
commissioners/other stakeholders.
trial registration number 76607611; Pre-results.
strengths and limitations of this study
 ► We designed our study using the framework recom-
mended by the Cochrane Bias and Non-Randomised 
Studies Methods Groups for establishing appropriate 
patient populations, interventions and follow-up to 
emulate three hypothetical randomised controlled 
trials (target trials).
 ► We will identify potential confounders systematically 
using literature review, semistructured interviews 
with clinicians (cardiologists, cardiac surgeons and 
general practitioners) and a short survey with an ad-
ditional group of clinicians.
 ► Because there are no medication data in Hospital 
Episode Statistics, we will assume that patients’ 
first dual antiplatelet therapy (DAPT) prescription 
that appears in Clinical Practice Research Datalink 
(CPRD) after their hospital admission is what they 
were prescribed at discharge.
 ► We will conduct sensitivity analyses to address the 
robustness of results to different assumptions about 
the unknown intervention group in patients who died 
or had a bleeding event before a DAPT prescription 
in CPRD.
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IntroduCtIon
Dual antiplatelet therapy (DAPT), a combination of 
aspirin and either clopidogrel, prasugrel or ticagrelor, 
is recommended for secondary prevention of ischaemic 
events (heart attack and stroke) in people with coronary 
artery disease. Guidelines recommend that patients are 
treated with DAPT for 6 to 12 months following myocar-
dial infarction (MI) and coronary interventions (percuta-
neous coronary intervention [PCI] and coronary artery 
bypass grafting [CABG])1–3 and support the use of the 
more potent antiplatelet inhibitors ticagrelor and pras-
ugrel.2 Antiplatelet agents reduce the risk of ischaemic 
events, by preventing the formation of clots in athero-
sclerotic coronary arteries and within stents (following 
PCI) or grafts (following CABG), but increase the risk 
of bleeding.4 Randomised controlled trials (RCTs) have 
shown that adding clopidogrel to aspirin leads to 1% 
excess risk of major bleeding (requiring admission to 
hospital) compared with aspirin alone.5 6 Prasugrel and 
ticagrelor reduce the risk of ischaemic events further but 
also further increase the risk of bleeding.7 Some patients 
(eg, those with existing atrial fibrillation or those who 
develop atrial fibrillation after PCI, CABG or acute coro-
nary syndrome [ACS]) are prescribed an anticoagulant 
(eg, warfarin, dabigatran, rivaroxaban, apixaban) in 
addition to DAPT (triple therapy [TT]), which further 
increases the risk of bleeding.
‘Real world’ bleeding events that do not require any 
intervention are likely to be much more frequent than 
those reported in RCTs, which excluded patients at high 
risk of bleeding and mainly reported only on major 
bleeding. Bleeding events that do not result in hospital-
isation are largely managed in primary care and may have 
a significant clinical and economic impact.8 Minor and 
nuisance bleeding (nose and gum bleeds, bruising and 
prolonged bleeding from cuts) may also reduce adher-
ence to DAPT9 and non-adherent patients may be at 
increased risk of a secondary ischaemic episode.10 Only 
three studies have reported the incidence and conse-
quences of nuisance bleeding after DAPT11–13; these 
suggest that nuisance bleeding is common (affecting 
29%–38% of patients) and impacts on adherence (11% 
of patients in one study discontinued clopidogrel12). 
A nested case–control study using the Health Improve-
ment Network (a UK primary care database) reported 
an increased risk of upper gastrointestinal bleeding with 
clopidogrel and aspirin compared with aspirin alone 
(relative risk, 2.08; 95% CI 1.34 to 3.21).14
The economic impact of bleeding events associated 
with DAPT is also poorly characterised, in particular for 
minor bleeding events and their impact on health-related 
quality of life.8 This is not surprising given that health 
economic analyses often lack detailed data on adverse 
effects of interventions, despite consensus that such 
effects should be considered.15 16 To ensure appropriate 
decisions are made about which DAPT regimens to use 
in clinical practice, the health and resource use conse-
quences of minor and major bleeding events should be 
incorporated into assessments of cost-effectiveness. For 
DAPT, this entails accounting for uncertainty in the abso-
lute risk of bleeding, the impact of different bleeding 
events on health-related quality of life and treatment 
adherence and subsequent risk of secondary ischaemic 
events and the cost implications of managing these 
bleeding events.
We propose to use Hospital Episode Statistics (HES) 
and the Clinical Practice Research Datalink (CPRD) 
databases to estimate the incidence of all bleeding 
events occurring in patients prescribed different DAPT 
or TT regimens after undergoing coronary interven-
tions (PCI and CABG) and in conservatively managed 
patients with ACS. Our study will also provide param-
eter estimates to update existing cost-effectiveness 
models. We will use the framework recommended 
by the Cochrane Bias and Non-Randomised Studies 
Methods Groups for establishing appropriate patient 
populations, interventions and follow-up to emulate 
the following three hypothetical RCTs (hereafter 
referred to as the target trials, table 1)17.
1. In patients who have undergone PCI, estimate the ef-
fect on bleeding events of assignment to aspirin and 
clopidogrel (reference) versus aspirin and prasugrel 
or aspirin and ticagrelor.
2. In patients who have undergone CABG, estimate the 
effect on bleeding events of assignment to aspirin (ref-
erence) versus aspirin and clopidogrel.
3. In patients who are conservatively managed after 
presenting with ACS, estimate the effect on bleeding 
events of assignment to aspirin (reference) versus aspi-
rin and clopidogrel.
Methods
Data sources
CPRD is a database of primary care electronic health 
record data (available online via CPRD GOLD) from 
participating general practices, covering 7% of the UK 
population.18 Patients included in CPRD are largely 
representative of the UK population in terms of age, 
sex, ethnicity and body mass index. HES covers all 
hospital admissions for all English patients whose 
treatment is funded by the UK National Health Service 
(NHS), whether treated by the NHS or by independent 
providers.19 Seventy-five per cent of English general 
practices included in CPRD are linked to HES data.18 
We obtained data from 1 April 2009 to 31 July 2017; 
this period covers the introduction of the newer anti-
platelet agents prasugrel and ticagrelor. This study 
protocol has been approved.
study populations
Eligibility and exclusion criteria for the three target trials 
(for patients undergoing PCI, patients undergoing CABG 
or patients hospitalised and conservatively managed for 
ACS) are listed in table 1. We will identify eligible patients 
who are included in Clinical Practice Research Datalink 
(CPRD) and eligible for linkage with Hospital Episode 
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Table 1 Summary of three target trials and how observational data will be used to emulate these
PICO 
component Target trial
Issues in emulating the target trial using 
observational data
Eligibility criteria Target trial 1 (PCI)
Consecutive patients (age ≥18 years) undergoing PCI 
(emergency or elective). Exclusions: DAPT or anticoagulant 
use in the previous 3 months; major bleed requiring 
hospitalisation in previous 12 months; renal failure requiring 
dialysis; intolerance/allergy to aspirin, clopidogrel, 
prasugrel or ticagrelor.
Target trial 2 (CABG)
Consecutive patients (age ≥18 years) undergoing CABG 
(urgent and elective). Exclusions: DAPT or anticoagulant 
use in the previous 3 months; other concomitant cardiac 
surgery (eg, valve surgery); major bleed requiring 
hospitalisation in previous 12 months; renal failure requiring 
dialysis; intolerance/allergy to aspirin, clopidogrel, 
prasugrel or ticagrelor.
Target trial 3 (conservatively managed ACS)
Consecutive patients (age ≥18 years) hospitalised for an 
acute coronary syndrome (ACS): myocardial infarction 
(MI) with or without ST elevation or unstable angina. 
Exclusions: PCI or CABG performed at time of ACS 
diagnosis; major bleed requiring hospitalisation in previous 
12 months; renal failure requiring dialysis; intolerance/
allergy to aspirin, clopidogrel, prasugrel or ticagrelor.
CPRD-HES linked data set contains information 
that allows us to identify all eligible patients 
for the three target trials. The study period is 
April 2009–July 2017. All eligible patients will 
have sufficient data (1 year) preceding their 
index event to apply the exclusion criteria and 
characterise the population (eg, comorbidities) 
and sufficient follow-up data (1 year) to 
identify outcomes. It is not possible to capture 
intolerance/allergy to aspirin, clopidogrel, 
prasugrel or ticagrelor.
Interventions Target trial 1 (PCI)
Clopidogrel (75 mg daily) or prasugrel (5 mg or 10 mg 
daily) or ticagrelor (90 mg twice daily). All patients will 
receive aspirin (at a dose of 75 mg daily, in line with current 
guidelines).
Target trial 2 (CABG)
Clopidogrel (75 mg) in addition to aspirin (at a dose of 
75 mg daily, in line with current guidelines) or aspirin only 
(any dose, reflecting variation in usual care).
Target trial 3 (conservatively managed ACS)
As for target trial 2.
Relevant interventions can be identified as 
CPRD has information on all medications 
(including doses) prescribed in primary care.
Assignment to 
interventions
Participants are assigned to DAPT interventions in hospital. Participants enter the study at index procedure 
date for PCI and CABG, and episode start 
date for ACS, and will be assigned to DAPT 
interventions using first prescription in CPRD 
(within 2 months of hospitalisation) as a proxy for 
what they were prescribed in hospital (there are 
no medications data in HES). This assignment 
will exclude a proportion of eligible patients 
(those who died or experienced a major bleed 
that caused them to stop DAPT, or patients 
who have no prescription for DAPT within the 
2-month window); we will identify and describe 
the characteristics of these excluded patients.
In sensitivity analyses, we will address the 
robustness of results to different assumptions 
about the intervention group in those patients 
where the DAPT medication is unknown or 
a major bleed occurs prior to the first DAPT 
medication, by using multiple imputation 
models for handling missing data. Prior known 
information regarding the likely prescription 
based on patient characteristics or general 
policies will be incorporated in these analyses.
Continued
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Statistics (HES) and Office for National Statistics (ONS) 
mortality data (because they have a valid NHS number 
and are registered at a practice that was participating in 
the linkage programme). Patients are included if they had 
a PCI, CABG or ACS (index event) record in HES during 
the study period (1 April 2010–31 January 2017), and have 
at least 1 year of linked CPRD-HES data before the date of 
their index event. They must also have been prescribed 
one of the treatment regimens being compared in the 
target trial corresponding to their index event. One year’s 
data preceding eligibility for the target trial is adequate 
to apply most of the exclusion criteria and determine 
comorbidities and medication history: such information 
would be collected at baseline in a randomised trial. The 
following Office of Population Censuses and Surveys 
(OPCS) procedure codes (PCI and CABG) and Interna-
tional Classification of Diseases (ICD-10) codes (ACS no 
procedure) will be used to identify patients: PCI, K49, K50 
& K75; CABG, K40, K41, K42, K43, K44, K45 & K46; ACS 
without a procedure, I20.0, I21, I22, I24.9 (with no OPCS 
code for PCI or CABG in the same hospital admission). 
Figure 1 shows full details of the inclusion and exclusion 
criteria.
PICO 
component Target trial
Issues in emulating the target trial using 
observational data
Follow-up Starts at assignment to intervention and ends at first bleed 
or 12 months from assignment (whichever comes first).
Starts at time of hospitalisation for PCI, CABG or 
ACS and ends at first bleed or 12 months from 
hospitalisation (whichever comes first).
Primary 
outcome
Any bleed within 12 months of the start of DAPT (DAPT is 
prescribed at hospitalisation for PCI, CABG or ACS).
Any bleed within 12 months of hospitalisation for 
PCI, CABG or ACS.
Analysis Intention to treat According to first prescription for DAPT in CPRD
CABG, coronary artery bypass grafting; CRPD, Clinical Practice Research Datalink; DAPT, dual antiplatelet therapy; HES, Hospital Episode 
Statistics; PCI, percutaneous coronary intervention; PICO, Population, intervention, comparator, outcome.
Table 1 Continued 
Figure 1 Study diagram describing the construction of the PCI, CABG and ACS (conservatively managed) populations.
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Interventions
The interventions of interest for the three target trials are 
shown in table 1. Guidelines recommend low dose aspirin 
(75 to 100 mg/d) plus either clopidogrel (75 mg/d), 
prasugrel (5 mg/d or 10 mg/d) or ticagrelor (90 mg 
twice/d) for PCI and conservatively managed patients 
with ACS. For PCI patients, the interventions of interest 
are aspirin and clopidogrel, aspirin and prasugrel and 
aspirin and ticagrelor. In conservatively managed patients 
with ACS, clopidogrel is the most commonly prescribed 
second antiplatelet agent (in addition to aspirin) and a 
large proportion of patients are prescribed aspirin only; 
therefore, the interventions of interest are aspirin only 
(75 to 100 mg/day) and aspirin and clopidogrel. There 
is variation in aspirin prescription for CABG patients; 
some surgeons choose 75 mg/day, others 150 mg/day or 
300 mg/day. Surgeons may also prescribe an additional 
antiplatelet agent, most commonly clopidogrel. There-
fore, the comparisons of interest in CABG patients are 
aspirin only (any dose, reflecting variations in usual care 
in different hospitals) and aspirin and clopidogrel (doses 
as for PCI). We have specified these comparisons based 
on preliminary feasibility counts from CPRD, which indi-
cate that few CABG and conservatively managed patients 
with ACS are prescribed aspirin and prasugrel or aspirin 
and ticagrelor.
In the target trials, the interventions would be assigned 
during the hospital stay, as soon as patients are eligible 
for antiplatelet therapy. Our observational data set does 
not have information on medication given to patients at 
discharge, because HES does not include medications 
data. Therefore, the first time at which we have infor-
mation on the antiplatelet regimen to which patients 
were assigned in hospital is when they receive their 
first primary care prescription/s for aspirin or DAPT, 
recorded in CPRD. It is reasonable to use these as a proxy 
for the medications that patients started in hospital, 
because patients’ general practitioners (GPs) are unlikely 
to change the prescriptions that were started in hospital.
We will classify patients according to the first prescrip-
tion recorded in CPRD during the first 2 months after 
hospitalisation for PCI, CABG or ACS. This 2-month 
window is based on variability in the amount of DAPT 
medication provided to patients in hospital following 
their PCI, CABG or ACS and hence variability in the time 
when they first request a repeat prescription from their 
general practice. A preliminary investigation showed 
that more than 75% of eligible patients have a prescrip-
tion for one or more antiplatelet agents during this time 
period. If a patient only has a prescription for aspirin 
during the 2-month window after hospital discharge, 
they will be assigned to an aspirin only intervention. If 
patients also receive a prescription for clopidogrel, pras-
ugrel or ticagrelor, they will be assigned to aspirin/clopi-
dogrel, aspirin/prasugrel or aspirin/ticagrelor. If there is 
a prescription for more than one additional antiplatelet 
agent in the 2-month window, we will assign the patient to 
an intervention based on the agent prescribed first. For 
example, if a patient has an aspirin prescription and a 
prescription for clopidogrel before a prescription for tica-
grelor, the patient will be assigned to the aspirin/clopido-
grel intervention. Patients with no prescriptions in CPRD 
for aspirin, or aspirin and clopidogrel, prasugrel or tica-
grelor within the 2-month window will be excluded from 
the main analysis. We will conduct sensitivity analyses of 
all eligible patients including those with unknown DAPT 
regimens or a major bleed prior to first DAPT prescrip-
tion, by estimating assignment to DAPT interventions for 
those with no prescription data using multiple imputa-
tion based on a range of assumptions.20
outcomes
The primary outcome will be any bleeding event, clas-
sified as type 2–5 by the Bleeding Academic Research 
Consortium (BARC) bleeding scale.21 For each patient, 
we will identify all bleeding events in HES and CPRD 
during follow-up. We will not be able to identify BARC 
type 1 bleeding events (bleeding that is not actionable 
and does not cause the patient to seek treatment) as type 
1 assumes there is no interaction with the health system 
or healthcare professionals; therefore, no bleed event 
will be recorded in HES or CPRD. We have specified a 
comprehensive list of bleeding codes in CPRD and HES 
(see online supplementary appendix 1). These will be 
categorised according to anatomical site for descriptive 
purposes. Secondary outcomes will be: any major bleeding 
event (leading to hospital admission, inpatient HES); 
any minor bleeding event (recorded within CPRD data); 
all-cause mortality; cardiovascular mortality; mortality 
from bleeding (these will be identified from linked ONS 
data); MI; stroke; additional coronary intervention.
Follow-up
The start of follow-up (the index event) will be the date of 
the index hospital procedure (PCI, CABG) or start date 
of the hospital episode that contains the ACS diagnosis 
(ACS). Patients will be followed up until 12 months after 
the index event, since DAPT is prescribed for 12 months 
in accordance to guidelines.
Confounding and cointerventions
Potential confounders (variables that predict both risk 
of bleeding and intervention group) will be specified 
a priori.22 23 We will identify confounders and cointer-
ventions using literature review and clinician expertise 
as recommended by the Cochrane Bias and Non-Ran-
domised Studies Methods Groups.17 We will carry out a 
comprehensive and systematic literature search to iden-
tify all RCT and cohort studies of DAPT interventions, or 
cohort studies that identify predictors of bleeding. The 
literature searches for the review are included in supple-
mentary appendix 2. Abstracts will be screened by one 
researcher and full-text papers will be obtained. Data on 
confounders and cointerventions will be extracted by two 
researchers independently using a data extraction form 
specifically designed for the study; variables extracted 
 o
n
 1 July 2019 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2019-029388 on 4 June 2019. Downloaded from 
6 Pufulete M, et al. BMJ Open 2019;9:e029388. doi:10.1136/bmjopen-2019-029388
Open access 
will include study characteristics, population character-
istics (reported in the tables of baseline characteristics), 
factors adjusted for in the statistical analyses and factors 
reported to predict risk of bleeding in our populations. 
We will not perform a risk of bias assessment because the 
aim of the review is only descriptive (ie, the output will be 
lists of confounders and cointerventions) and there are 
no established criteria for assessing the validity with which 
primary researchers consider potential confounders and 
cointerventions; therefore, it would be inappropriate to 
apply a risk-of-bias tool for studies estimating a treatment 
effect. We will use ‘saturation’ as a criterion for discontin-
uing data collection, defined as review of 10 consecutive 
studies without identifying an additional confounder/
cointervention.
In parallel, we will conduct semiquantitative interviews 
with six clinicians in each of three groups: cardiologists; 
cardiac surgeons and GPs (to determine whether DAPT 
prescriptions are changed in primary care). The main 
aim of the clinician interviews is to understand DAPT 
prescribing practice in the UK and identify the factors 
(relating to patients, centres and prescribing practices 
of the individual doctors) that influence the decision 
about which antiplatelet regimen to prescribe. All factors 
that influence DAPT prescribing (confounders) identi-
fied from the literature review and clinician interviews 
will be combined in a short survey (SurveyMonkey). 
The survey questionnaire will be administered online 
to all consultant members of the British Cardiovascular 
Society (cardiologists) and the Society for Cardiothoracic 
Surgery (cardiac surgeons). The survey will be either 
emailed to all members individually (if the professional 
bodies agree) or advertised in weekly/monthly news-
letters. Confounders will be grouped in confounding 
domains.17 We will attempt to identify each potential 
confounder (identified through the literature review, 
clinician interviews and survey) in the CPRD or HES 
data set but acknowledge that there may be missing data 
across patients (and time) for some confounders.
sample size
Estimated rates of bleeding with the different thera-
pies are 5% for aspirin, 9% for aspirin/clopidogrel and 
12% for aspirin/prasugrel and aspirin/ticagrelor.5 6 24 25 
Preliminary feasibility counts provided by CPRD suggest 
that there will at least the following numbers of patients 
eligible for each target trial:
PCI: aspirin/clopidogrel (reference, 6738 patients) 
versus aspirin/prasugrel (842 patients) or aspirin/tica-
grelor (770 patients)
CABG: aspirin (reference, 2556 patients) versus aspi-
rin/clopidogrel (595 patients)
Conservatively managed ACS: aspirin (reference, 8148 
patients) versus aspirin/clopidogrel (3082 patients)
These estimates give expected event rates of at least 
700 for PCI, 180 for CABG and 680 for ACS, assuming 
a ratio of 8:1 (aspirin/clopidogrel:aspirin/prasugrel 
or aspirin/clopidogrel:aspirin/ticagrelor) for PCI, 4:1 
(aspirin:aspirin/clopidogrel) for CABG and 2.5:1 (aspir-
in:aspirin/clopidogrel) for ACS. The HR detectable 
with 90% and 80% power at the 5% statistical signifi-
cance, assuming the group ratios given above, are shown 
in table 2. The correlation of the DAPT with other covar-
iates adjusted for is unknown and we assessed the impact 
of a range of correlations (0, 0.3 and 0.5).
statistical analyses
We will describe temporal changes in DAPT prescribing 
and bleeding for PCI, CABG and ACS populations. We 
will use descriptive statistics to summarise the characteris-
tics of the different intervention groups and standardised 
mean differences to compare them. We will estimate rates 
of bleeding (number of events/person time) with 95% 
CIs for each group. We will separate major and minor 
Table 2 HR for a range of correlations for percutaneous coronary intervention (PCI), coronary artery bypass grafting (CABG) 
and acute coronary syndrome (ACS)
Ratio of presence: absence 
of covariate
Squared correlation with 
other covariates
HR detectable
90% power 80% power
PCI
  8:1 0 (ie, unadjusted) 1.48 1.41
0.3 1.60 1.50
0.5 1.74 1.62
CABG
  4:1 0 (ie, unadjusted) 1.83 1.69
0.3 2.06 1.87
0.5 2.35 2.10
Conservatively managed ACS
  2.5:1 0 (ie, unadjusted) 1.32 1.27
0.3 1.39 1.33
0.5 1.48 1.40
 o
n
 1 July 2019 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2019-029388 on 4 June 2019. Downloaded from 
7Pufulete M, et al. BMJ Open 2019;9:e029388. doi:10.1136/bmjopen-2019-029388
Open access
bleeding since adverse events of each type have different 
health and resource use consequences.
Analyses will estimate the effects of assigned inter-
vention (analogous to an intention-to-treat analysis of 
a randomised trial) for the antiplatelet regimens corre-
sponding to the first prescription of aspirin or DAPT in 
CPRD (see Interventions). We will use parametric survival 
models to estimate adjusted HRs with 95% CIs for the time 
to first bleeding event, comparing intervention groups for 
each target trial. Exploratory analyses, including assess-
ment of proportional hazards assumptions, will be used to 
inform the choice of survival distribution (eg, Weibull). 
Estimated time-dependent event probabilities will be 
used to update existing cost-effectiveness models.26 The 
confounding factors to be included in the model (which 
will be identified as described previously and grouped into 
confounding domains from our data set), the modelling 
strategy and the approach to handling correlated covari-
ates will be documented in a data analysis plan. Partici-
pants free from a bleeding event will be censored at 12 
months after the index event. For secondary endpoints, 
we will use survival models to estimate adjusted HRs with 
95% CIs for time to first event. For mortality outcomes, 
we will take account of the competing risks of death due 
to other causes.
We will perform three sets of sensitivity analyses:
1. We will address the unknown intervention group of 
eligible patients who have no prescription data and 
therefore cannot be assigned to an intervention (ie, 
those that died before receiving their first prescription, 
had a major bleed which caused them to stop DAPT or 
have no aspirin/DAPT prescription recorded in CPRD 
within the 2-month window). These analyses will be un-
dertaken using multiple imputation methods to deal 
with missing information on DAPT medication and 
will take patient characteristics, procedure/diagnosis 
and general medication policies into account, using a 
range of assumptions.
2. We will address the possibility that some minor bleeding 
events are not documented in CPRD but nevertheless 
prompt medication changes. We anticipate that most 
bleeding events will occur soon after the index event and 
before any medication change. Medication changes will 
be described relative to bleeding events observed (eg, 
before event, after event, no bleeding event observed). 
If a substantial proportion (>10%) of people change 
medication before their first bleeding event, we will per-
form a sensitivity analysis excluding these patients.
3. We will assess the sensitivity of our findings when the 
analysis is restricted to a subpopulation of patients at 
low risk of bleeding (ie, excluding people at high risk 
for bleeding) who, we hypothesise, have the lowest risk 
of residual confounding.
We will attempt to identify an instrumental variable (eg, 
clinician/GP practice prescribing practice) to control for 
confounding by indication. If we are successful, we will 
repeat the above analyses for the PCI, CABG and ACS 
populations.
Figure 2 Study diagram describing the construction of the triple therapy (TT) populations.
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We will explore the consistency of treatment effect esti-
mates in the following subgroups: ACS versus non-ACS 
(PCI and CABG populations); diabetic versus non-dia-
betic; chronic kidney disease versus non-chronic kidney 
disease; concurrent prescription for proton pump inhib-
itors versus no prescription for proton pump inhibitors. 
All subgroups will be defined in the data analysis plan and 
chosen based on the characteristics of the analysis popu-
lations before carrying out any analyses by intervention 
group. We will report p values from tests of interaction.
triple therapy
We will establish additional groups of patients (PCI or 
CABG or conservatively managed ACS) based on TT 
prescription. The main reason for prescribing an anti-
coagulant is to treat atrial fibrillation in a patient other-
wise eligible for either of the three target trials. Atrial 
fibrillation can precede (long-term anticoagulation 
for pre-existing atrial fibrillation) or follow the index 
event (anticoagulation for new-onset atrial fibrillation). 
Figure 2 shows how the patient groups receiving TT will 
be constructed.
We will identify patients on long-term anticoagula-
tion by identifying prescriptions of oral anticoagulants 
(warfarin, dabigatran, rivaroxaban, apixaban) in the 
3 months before their index event and a concomitant 
prescription of any anticoagulant (TT) with DAPT and 
in the first 2 months after the index admission. Patients 
who develop atrial fibrillation after the index event will 
be identified from any new anticoagulant prescription 
during follow-up. We have compiled a list of all drug codes 
in CPRD for antiplatelet agents (aspirin, clopidogrel, 
prasugrel and ticagrelor) and anticoagulants (warfarin, 
dabigatran, rivaroxaban, apixaban) (see supplementary 
appendix 3).
In patients receiving various TT regimens (grouped 
by pre-index event anticoagulant prescription and post-
index event anticoagulant prescription in PCI, CABG 
and ACS separately, see figure 2), we will describe rates of 
bleeding (number of events/person time) with 95% CIs 
for each group. We have not specified comparison groups 
because we know there is large variation in prescribing 
of anticoagulants; TT is usually prescribed for a rela-
tively short period of time (1–6 months, depending on 
a patient’s individual risks of thrombosis and bleeding) 
after which an antiplatelet agent (usually aspirin) is 
removed and patients continue to receive an anticoagu-
lant and single antiplatelet for the remainder of the 12 
months after the index admission.
Patient and public involvement
We set up a patient advisory group comprising of patients 
from our three cohorts (PCI, CABG and conserva-
tively managed ACS). The group was consulted about 
several aspects of the proposed study. Group members 
confirmed the importance of the research topic and 
agreed that the choice of antiplatelet regimen should 
be based on shared decision making, with clinicians 
and patients weighing the potential benefits against the 
adverse side effects and practical inconvenience. Our PPI 
group will attend regular meetings to discuss results from 
the study and will also contribute and collaborate on the 
development of our results dissemination strategy.
Ethics and dissemination
This study protocol has approval. We also obtained ethical 
approval for the semistructured interviews with clinicians 
and survey from South West Cornwall and Plymouth 
Research Ethics Committee, 17/SW/0092. The findings 
will be presented at national/international conferences, 
published in peer-reviewed academic journals and acces-
sible formats in newsletters to patients (where available). 
The findings will also be reported as a briefing paper 
to commissioners (eg, commissioning groups, National 
Institute for Health and Care Excellence) and to other 
healthcare stakeholders with an interest in the research 
through the Cardiac & Stroke Networks. We will also 
present and discuss our results at local CPRD working 
groups to disseminate methods to other researchers using 
the CPRD database.
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